As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
10 Years of Molecular Autism
This year marks a decade since Molecular Autism was established to accelerate and integrate research into neurodevelopmental conditions.
Read our retrospective collection of the most impactful publications from the last ten years here.
Announcing the launch of In Review
In partnership with Research Square, Molecular Autism is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Read more about the full range of benefits of In Review and how to opt in, or see the In Review platform for yourself here.
Articles
-
-
Targeting PPARα in the rat valproic acid model of autism: focus on social motivational impairment and sex-related differences
-
Coping, fostering resilience, and driving care innovation for autistic people and their families during the COVID-19 pandemic and beyond
-
Does decreased visual attention to faces underlie difficulties interpreting eye gaze cues in autism?
-
Empathic disequilibrium in two different measures of empathy predicts autism traits in neurotypical population
-
Hans Asperger, National Socialism, and “race hygiene” in Nazi-era Vienna
-
Quantifying compensatory strategies in adults with and without diagnosed autism
-
Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses
-
Common genetic variants, acting additively, are a major source of risk for autism
-
Sex and gender differences in autism spectrum disorder: summarizing evidence gaps and identifying emerging areas of priority
Call for Papers - Open Collections
Editors-in-Chief
Simon Baron-Cohen, University of Cambridge, UK
Joseph Buxbaum, Icahn School of Medicine at Mount Sinai, New York
Aims and scope
Molecular Autism is a peer-reviewed, open access journal that publishes high-quality basic, translational and clinical research that has relevance to the etiology, pathobiology, or treatment of autism and related neurodevelopmental conditions. Research that includes integration across levels is encouraged. Molecular Autism publishes empirical studies, reviews, and brief communications.
We encourage submissions from a range of fields including (but not restricted to) genetics, molecular neurobiology, neuropathology, neuroimaging, cognitive neuroscience, epidemiology, and biomarker discovery. Molecular Autism also publishes articles on screening, diagnosis and classification, including articles that consider subgrouping to refine our understanding of basic mechanisms. Intervention studies are also welcome, especially when considered with respect to revealing causal mechanisms.
Joseph Buxbaum, co-Editor-in-Chief
Joseph Buxbaum is a molecular geneticist and neuroscientist, Director of the Seaver Autism Center for Research and Treatment, and Professor at the Icahn School of Medicine at Mount Sinai. Dr Buxbaum is the founder and co-lead investigator of the Autism Sequencing Consortium, an international collaboration to discover genes for autism. He has also been elected to the prestigious National Academy of Medicine (NAM), in recognition of his important contributions to uncovering the genetic and molecular basis of autism.
Simon Baron-Cohen, co-Editor-in-Chief
Simon Baron-Cohen is Professor of Developmental Psychopathology at the University of Cambridge and Fellow at Trinity College, Cambridge. He is also Director of the Autism Research Centre (ARC) in Cambridge and Director of CLASS (Cambridge Lifespan Asperger Syndrome Service), a clinic for adults with suspected AS.
Follow
Annual Journal Metrics
-
Speed
79 days to first decision for reviewed manuscripts only
56 days to first decision for all manuscripts
175 days from submission to acceptance
34 days from acceptance to publication
Citation Impact
5.712 - 2-year Impact Factor
6.283 - 5-year Impact Factor
1.458 - Source Normalized Impact per Paper (SNIP)
2.526 - SCImago Journal Rank (SJR)
Usage
506,071 downloads
1,963 Altmetric mentions
